About Us
Our Mission
Leadership
Partnerships
Careers
Contact Us
Our Science
SCY-247
Ibrexafungerp
Life-threatening Infections
Pipeline
Publications and Presentations
News
News
Events
Careers
Investors
Sitemap
About
Our Mission
Leadership
Partnerships
Careers
Contact Us
Our Science
SCY-247
Ibrexafungerp
Life-threatening Infections
Invasive Candidiasis
Invasive fungal infections
Pipeline
Publications and Presentations
Vulvovaginal candidiasis
Recurrent vulvovaginal candidiasis
News
Events
Contact Us
Investors
News Releases
Events & Presentations
Governance
Financials & Filings
Stock Data
Expanded Access
Privacy Policy
Disclaimer
Sitemap
×
Announcement
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
View Press Release
SCYNEXIS Announces $40 million Private Placement
View Press Release